Infusion Rate Card

briumvi™
ublituximab-xiiy 150 mg/6 mL injection for IV

Dilute BRIUMVI into a PVC or PO infusion bag containing 0.9% NaCl injection

See accompanying full Prescribing Information for full Dosing and Administration instructions.

Administer BRIUMVI under the close supervision of an experienced healthcare professional with access to appropriate medical support to manage severe reactions such as serious infusion reactions.

FIRST INFUSION

BRIUMVI dose	Total volume	Infusion rate				Total duration*
		0-30 min	30 min-hour 1	Hours 1-2	Hours 2-4	
150 mg	250 mL	10 mL/hr	20 mL/hr	35 mL/hr	100 mL/hr	4 hours

SECOND INFUSION 2 weeks after the first infusion

BRIUMVI dose	Total volume	Infusion rate		Total duration*
		0-30 min	30 min-hour 1	
450 mg	250 mL	100 mL/hr	400 mL/hr	1 hour

SUBSEQUENT INFUSIONS once every 24 weeks. Administer the first subsequent infusion 24 weeks after the first infusion

BRIUMVI dose	Total volume	Infusion rate		Total duration*
		0-30 min	30 min-hour 1	
450 mg	250 mL	100 mL/hr	400 mL/hr	1 hour

- Premedicate with a **corticosteroid** and an **antihistamine** administered orally or intravenously approximately **30-60 minutes** prior to each infusion to reduce the frequency and severity of infusion reactions. The addition of an antipyretic may also be considered
- Observe the patients for at least 1 hour after the first 2 infusions. Post-infusion monitoring of subsequent infusions is at physician discretion unless infusion reaction and/or hypersensitivity has been observed in association with the current or any prior infusion

*Infusion duration may take longer if the infusion is interrupted or slowed.
PO, polyolefin; PVC, polyvinyl chloride.

This Infusion Rate Card is not a substitute for the full Prescribing Information.
Please see selected Important Safety Information and accompanying full Prescribing Information.

INDICATION

BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

SELECTED IMPORTANT SAFETY INFORMATION

Contraindications: BRIUMVI is contraindicated in patients with active hepatitis B virus infection and a history of life-threatening infusion reaction to BRIUMVI.

WARNINGS AND PRECAUTIONS

Infusion Reactions: BRIUMVI can cause infusion reactions, which can include pyrexia, chills, headache, influenza-like illness, tachycardia, nausea, throat irritation, erythema, and an anaphylactic reaction.

Observe treated patients for infusion reactions during the infusion and for at least one hour after the completion of the first two infusions unless infusion reaction and/or hypersensitivity has been observed in association with the current or any prior infusion. Inform patients that infusion reactions can occur up to 24 hours after the infusion. Administer the recommended pre-medication to reduce the frequency and severity of infusion reactions. If life-threatening, stop the infusion immediately, permanently discontinue BRIUMVI, and administer appropriate supportive treatment.

Infections: Delay BRIUMVI administration in patients with an active infection until the infection is resolved.

Vaccinations: Administer all immunizations according to immunization guidelines: for live or live-attenuated vaccines at least 4 weeks and, whenever possible at least 2 weeks prior to initiation of BRIUMVI for non-live vaccines.

Fetal Risk: A pregnancy test is recommended in females of reproductive potential prior to each infusion.

Reduction in Immunoglobulins: Monitor the levels of quantitative serum immunoglobulins during treatment, especially in patients with opportunistic or recurrent infections, and after discontinuation of therapy until B-cell repletion.

Most Common Adverse Reactions: The most common adverse reactions in RMS trials (incidence of at least 10%) were infusion reactions and upper respiratory tract infections.

Reference

BRIUMVI [prescribing information]. New York, NY: TG Therapeutics, Inc.; 2022.

This Infusion Rate Card is not a substitute for the full Prescribing Information.

Please see selected Important Safety Information and accompanying full Prescribing Information.

TG Therapeutics

January 2023 US-UBL-2200082

briumvi™
ublituximab-xiiy 150 mg/6 mL injection for IV